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Introduction: The primary analysis of this open-label,
randomized, multicenter phase 3 study revealed no signif-
icant difference in progression-free survival between
pemetrexed plus cisplatin followed by maintenance geﬁti-
nib (PC/G) and geﬁtinib monotherapy (G) in patients with
advanced nonsquamous non–small cell lung cancer (NSCLC)
and unknown epidermal growth factor receptor gene
(EGFR) mutation status; however, the hazard ratio favored
PC/G. This report describes the ﬁnal overall survival (OS)
results.
Methods: Chemonaive, East Asian light ex-smokers/never-
smokers with advanced nonsquamous NSCLC and un-
known EGFR mutation status were randomized (1:1) to
PC/G (n ¼ 118) or G (n ¼ 118). EGFR mutation status was
retrospectively determined for 76 patients, 52 (68.4%) of
whom had EGFR-mutated tumors (exon 19 deletions in 26
and L858R point mutation in 24). OS was analyzed by the
Kaplan-Meier method. The study was registered at
ClinicalTrials.gov (NCT01017874).
Results: Median OS was similar in the PC/G (26.9 months)
and G (27.9 months) groups (hazard ratio ¼ 0.94, 95%
conﬁdence interval: 0.68–1.31, p ¼ 0.717). Median OS wasJournal of Thoracic Oncology Vol. 11 No. 3: 370-379longer with PC/G than with G in patients with EGFR wild-
type tumors (28.4 versus 8.9 months) and longer with G
than with PC/G in patients with EGFR-mutated tumors
March 2016 Pemetrexed plus Cisplatin Followed by Geﬁtinib 371(45.7 versus 32.4 months), especially those with exon 19
deletions. Second-line postdiscontinuation therapy was
common and included chemotherapy (PC/G, 41 of 118
[34.7%]; G, 73 of 118 [61.9%]) and rechallenge with an
EGFR tyrosine kinase inhibitor (PC/G, 27 of 118 [22.9%]; G,
9 of 118 [7.6%]).
Conclusions: The progression-free survival and OS results
from this study further demonstrate the importance of
determining EGFR mutation status to select the most appro-
priate ﬁrst-line treatment for patients with advanced NSCLC.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Lung cancer is a major cause of cancer mortality in
East Asia, accounting for approximately one-quarter of
cancer deaths.1 As there are currently no pan-Asian
guidelines for the treatment of non–small cell lung can-
cer (NSCLC), practitioners in Asia rely on guidelines
issued by organizations such as the National Compre-
hensive Cancer Network, the American Society of Clinical
Oncology, and the American College of Chest Physicians.2
According to these guidelines, the current standard of
care for chemonaive patients with advanced NSCLC and a
good performance status is platinum-based, two-drug
chemotherapy regimens.3–5 For patients whose tumors
have activating epidermal growth factor receptor gene
(EGFR) mutations, EGFR tyrosine kinase inhibitors (TKIs)
such as geﬁtinib and erlotinib are the preferred ﬁrst-line
treatment option.3,5 Activating EGFR mutations are com-
mon in patients with the following clinical characteristics:
female sex, East Asian ethnicity, history of nonsmoking,
and histologic diagnosis of adenocarcinoma.6–8 The two
most common activating EGFRmutations are deletions in
exon 19 and the L858R point mutation in exon 21, which
together account for approximately 85% to 90% of EGFR
somatic mutations in patients with NSCLC.8–10
A previously conducted randomized phase 3 study
compared pemetrexed plus cisplatin followed by main-
tenance geﬁtinib (PC/G) with geﬁtinib monotherapy (G)
in chemonaive patients with locally advanced or meta-
static nonsquamous NSCLC and unknown EGFRmutation
status at study entry.11 The patients in this study were
clinically selected for response to geﬁtinib treatment
(i.e., East Asian ethnicity, never-smokers or light ex-
smokers, and tumors with a histologic diagnosis of
adenocarcinoma). The primary analysis revealed nosigniﬁcant difference in progression-free survival (PFS)
between the PC/G and G groups in the intention-to-treat
(ITT) population, although the hazard ratio (HR) favored
PC/G (HR ¼ 0.85, 95% conﬁdence interval [CI]: 0.63–
1.13, p ¼ 0.261).11 In addition, a prespeciﬁed subgroup
analysis showed that PFS was not signiﬁcantly different
between the PC/G and G groups in patients with EGFR-
mutated tumors; however, PFS was signiﬁcantly longer
in the PC/G group than in the G group in patients with
EGFR wild-type tumors.11 The Iressa Pan-Asia Study
(IPASS) also assessed chemotherapy versus geﬁtinib
in chemonaive patients who had been clinically selected
for response to geﬁtinib.12 In this study, PFS was
signiﬁcantly longer with geﬁtinib than with carboplatin-
paclitaxel in the subgroup of patients with EGFR-
mutated tumors and signiﬁcantly longer with
carboplatin-paclitaxel than with geﬁtinib in the subgroup
of patients with EGFR wild-type tumors. The results of
these two studies support the current recommendation
that only patients with EGFR-mutated tumors should
receive an EGFR TKI as ﬁrst-line treatment.3,5
This phase 3 study has now been completed, and
here we report the overall survival (OS) data for the
PC/G and G groups in the ITT population and by EGFR
mutation status, along with the updated safety data. Also
reported here are post hoc analyses assessing the indi-
vidual effect of exon 19 deletions and the L858R point
mutation and the effect of systemic postdiscontinuation
therapy (PDT) on OS in the PC/G and G groups.
Materials and Methods
Study Design
Full details of the study design have been published
elsewhere.11 This was a multicenter, open-label, ran-
domized phase 3 study comparing PC/G with G in East
Asian patients with locally advanced or metastatic non-
squamous NSCLC. The study was conducted at 12 sites in
Hong Kong, the Republic of Korea, Singapore, Taiwan, and
Thailand. The study protocol was approved by the ethics
review board at each site and conducted in accordance
with Good Clinical Practice guidelines and the Declaration
of Helsinki. All patients provided written informed con-
sent before undergoing any study procedure. Separate
consent was obtained for the optional provision of tissue
samples for biomarker analysis. The study was registered
at www.ClinicalTrials.gov (NCT01017874).
Study Population
Chemonaive patients of East Asian ethnicity and un-
known tumor EGFR mutation status with stage IIIB (T4
malignant pleural effusion) or stage IV nonsquamous
NSCLC13,14 were eligible for inclusion in this study. Other
eligibility criteria included the following: age 18 years or
372 Yang et al Journal of Thoracic Oncology Vol. 11 No. 3older, a never-smoker (<100 cigarettes in one’s lifetime)
or light ex-smoker (had ceased smoking for at least 5
years and had not exceeded 10 pack-years), disease
measurable by Response Evaluation Criteria in Solid
Tumors version 1.0, and Eastern Cooperative Oncology
Group (ECOG) performance status (PS) of 0 or 1.
Randomization
Patients were randomly assigned (1:1) to receive
PC/G or G. Randomization was carried out using a
computer-generated random sequence and an inter-
active voice response system. Randomization was
stratiﬁed by baseline ECOG PS (0 or 1), sex (male or
female), smoking history (never-smoker or light ex-
smoker), and histologic diagnosis (adenocarcinoma or
nonadenocarcinoma).
Treatment Protocol
Full details of the treatment protocol have been
published elsewhere.11 Patients assigned to PC/G
received up to six cycles of pemetrexed (500 mg/m2
intravenously) followed approximately 30 minutes later
by cisplatin (75 mg/m2 intravenously), both of which
were administered on day 1 of 21-day cycles. After a
maximum of six cycles of PC (the induction period),
patients who had not progressed received oral G (250
mg/day) as maintenance therapy until progression,
discontinuation, or death (the maintenance period). Pa-
tients assigned to PC/G received dexamethasone, folic
acid, and vitamin B12 supplementation per the peme-
trexed label. Patients assigned to G received geﬁtinib
250 mg/day until progression, discontinuation, or death.
All patients were to be followed until death or study
completion.
EGFR Mutation Status
Where available, tumor tissue was analyzed for EGFR
mutations by means of a standardized Scorpions ARMS
EGFR mutation assay using an EGFR polymerase chain
reaction test kit (Qiagen, Valencia, CA). Tumors were
classiﬁed as EGFR wild type (EGFR wild-type subgroup),
EGFR mutation positive (EGFR-mutated subgroup), or
EGFR mutation status unknown. Tumor tissue was
assessed for exon 19 deletions (the Ex19del subgroup)
and the L858R point mutation in exon 21 (the L858R
subgroup).
Outcome Measures
Comparisons of OS between the PC/G and G groups in
the ITT population and by EGFR mutation status (which
were secondary objectives of the study) were performed.
In addition, post hoc analyses of OS in patients deter-
mined to have exon 19 deletions or the L858R pointmutation, and of OS by PDT, were conducted. OS was
deﬁned as the time from randomization to the date of
death from any cause. Treatment-emergent adverse
events (TEAEs) were reported according to the Medical
Dictionary for Regulatory Activities (version 15.1) and
graded using the National Cancer Institute Common
Terminology Criteria for Adverse Events (version 3.0).
Statistical Analysis
The ITT population comprised all patients who were
randomized to treatment. The safety population
comprised all patients who were randomized to treat-
ment and received at least one dose of pemetrexed,
cisplatin, or geﬁtinib. Median follow-up was calculated
using the reverse Kaplan-Meier method.15 OS was
analyzed using the Kaplan-Meier method and survival
curves were plotted. HRs were estimated using unad-
justed Cox regression analysis with assigned treatment
as the only covariate and analyzed using Wald’s test. PDT
was summarized as the number and percentage of pa-
tients using therapy and analyzed using Fisher’s exact
test. TEAEs were summarized as the number and per-
centage of patients reporting each event. The level of
signiﬁcance was set at p < 0.05. Analyses were per-
formed using SAS 9.2 software (SAS Institute, Cary, NC).
Results
Patient Disposition
Of the 253 patients entered in the study, 236 were
randomized to treatment (PC/G, 118 patients; G, 118
patients) and constituted the ITT population (Fig. 1). Of
the randomized patients, 232 received at least one dose
of pemetrexed, cisplatin, or geﬁtinib (PC/G, 114 patients;
G, 118 patients) and constituted the safety population
(see Fig. 1). Of the 236 patients in the ITT population,
149 (63.1%) consented to biomarker analyses and 142
(60.2%) provided tissue samples for EGFR mutation
analysis. EGFR mutation status could be determined for
76 (53.5%) of 142 tissue samples. Overall, 24 patients
had tumors that were classiﬁed as EGFR wild type and
52 patients had tumors that were classiﬁed as EGFR
mutated (mutation rate, 52 of 76 patients [68.4%];
Table 1). Of the 52 patients with EGFR-mutated tumors,
26 had exon 19 deletions and 24 had the L858R point
mutation (Table 1).
Demographic and Baseline Clinical
Characteristics
Demographic and baseline clinical characteristics
were similar between the PC/G and G groups (see
Table 1). Most patients (>90%) were never-smokers
and had stage IV disease. More than half of the pa-
tients had an ECOG PS of 1.
Figure 1. Patient ﬂow. G, geﬁtinib monotherapy; ITT, intention-to-treat; PC/G, pemetrexed plus cisplatin followed by
maintenance geﬁtinib.
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The censor rate was 40.7% and the median duration
of follow-up in the ITT population was 43.5 months
(95% CI: 39.3–47.3). There was no signiﬁcant difference
in OS between the PC/G and G groups in the ITT popu-
lation (Table 2 and Fig. 2A). Median OS was longer in the
PC/G group than in the G group in the EGFR wild-type
subgroup (see Table 2 and Fig. 2B). In contrast, me-
dian OS was longer in the G group than in the PC/G
group in the EGFR-mutated subgroup, the Ex19del sub-
group, and the L858R subgroup (see Table 2). However,
none of the observed differences in the OS Kaplan-Meier
curves between treatment groups in the EGFR subgroups
was statistically signiﬁcant. In the EGFR-mutated sub-
group (Fig. 2C) and the Ex19del subgroup (Fig. 2D), the
Kaplan-Meier survival curves were separated, with the
curve for the G group located above that for the PC/G
group. In contrast, in the L858R subgroup (Fig. 2E), the
Kaplan-Meier curves for the G and PC/G group over-
lapped somewhat.PDT
Most patients (>60%) in both the PC/G and G
groups received second-line PDT with systemic treat-
ment (Table 3). The proportion of patients whoreceived chemotherapy and a platinum doublet as
second-line PDT was signiﬁcantly higher (p < 0.001)
in the G group than in the PC/G group (see Table 3).
The proportion of patients who received an EGFR
TKI as second-line PDT was signiﬁcantly higher
(p ¼ 0.002) in the PC/G group than in the G group
(see Table 3). In the G group, OS appeared to be longer
in patients who received a pemetrexed platinum
doublet as second-line PDT than in patients who
received a nonpemetrexed platinum doublet (Fig. 2F).
Median OS was 34.9 months (95% CI: 21.3–42.3)
in patients who received a pemetrexed platinum
doublet (Pem) and 26.9 months (95% CI: 12.0–40.6) in
patients who received a nonpemetrexed platinum
doublet (Non-Pem) (HR ¼ 0.57, 95% CI: 0.29–1.14,
p ¼ 0.108).Safety and Tolerability Measures
The safety results were similar to those reported at
the time of the primary analysis.11 Throughout the study
period (the induction and maintenance periods com-
bined), most of the patients in both groups in the safety
population reported one or more possibly drug-related
TEAEs (PC/G, 104 of 114 patients [91.2%]; G, 99 of
118 patients [83.9%]). A higher proportion of patients in
Table 1. Patient Demographics and Baseline Disease Characteristics
Characteristic PC/G (n ¼ 118) G (n ¼ 118) Total (N ¼ 236)
Sex, n (%)
Male 30 (25.4) 29 (24.6) 59 (25.0)
Age, y
Mean (SD) 58.5 (10.73) 59.4 (10.67) 59.0 (10.69)
Age group, n (%)
<65 80 (67.8) 81 (68.6) 161 (68.2)
65 38 (32.2) 37 (31.4) 75 (31.8)
Smoking status, n (%)
Never-smoker 109 (92.4) 109 (92.4) 218 (92.4)
Light ex-smoker 9 (7.6) 9 (7.6) 18 (7.6)
Pathological diagnosis, n (%)
Adenocarcinoma 114 (96.6) 115 (97.5) 229 (97.0)
Nonadenocarcinoma 4 (3.4) 3 (2.5) 7 (3.0)
Stage of disease, n (%)
IIIB 6 (5.1) 8 (6.8) 14 (5.9)
IV 112 (94.9) 110 (93.2) 222 (94.1)
ECOG performance status, n (%)
0 49 (41.5) 49 (41.5) 98 (41.5)
1 69 (58.5) 69 (58.5) 138 (58.5)
Country of enrollment, n (%)
Hong Kong 3 (2.5) 7 (5.9) 10 (4.2)
Republic of Korea 54 (45.8) 60 (50.8) 114 (48.3)
Singapore 1 (0.8) 1 (0.8) 2 (0.8)
Taiwan 39 (33.1) 28 (23.7) 67 (28.4)
Thailand 21 (17.8) 22 (18.6) 43 (18.2)
EGFR mutation status, n (%)
EGFR wild type 13 (11.0) 11 (9.3) 24 (10.2)
EGFR mutated 27 (22.9) 25 (21.2) 52 (22.0)
Ex19del 15 (12.7) 11 (9.3) 26 (11.0)
L858R 10 (8.5) 14 (11.9) 24 (10.2)
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor gene; Ex19del, deletion in exon 19; G, geﬁtinib
monotherapy; L858R, point mutation in exon 21; PC/G, pemetrexed plus cisplatin followed by maintenance geﬁtinib; SD, standard
deviation.
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more possibly drug-related grade 3/4 TEAEs (PC/G, 40
of 114 patients [35.1%]; G, 20 of 118 patients [16.9%]).
The most commonly reported possibly drug-related
TEAEs were nausea, vomiting, and decreased appetite
in the PC/G group and rash, diarrhea, and pruritus in the
G group.Table 2. Overall Survival
Population (n)
Overall Survival, Median
PC/G
ITT (236) 26.9 (20.8–35.1)
EGFR wild type (24) 28.4 (11.3–50.6)
EGFR mutated (52) 32.4 (19.3–NE)
Ex19del (26) 32.4 (15.2–NE)
L858R (24) 35.7 (1.3–NE)
CI, conﬁdence interval; EGFR, epidermal growth factor receptor ge
monotherapy; ITT, intention-to-treat; L858R, point mutation in exon
by maintenance geﬁtinib.Discussion
The ﬁnal OS results from this randomized phase
3 study of chemonaive East Asian patients with
advanced NSCLC and unknown EGFR mutation status
at study entry showed that there was no signiﬁcant
difference in OS between patients receiving PC/G and
those receiving G. When analyzed by EGFR mutation(95% CI), mo
PC/G vs. G
HR (95% CI; p Value)G
27.9 (21.3–32.4) 0.94 (0.68–1.31; 0.717)
8.9 (0.7–NE) 0.62 (0.22–1.72; 0.356)
45.7 (25.8–NE) 1.57 (0.72–3.39; 0.255)
45.7 (18.7–NE) 2.36 (0.70–7.92; 0.166)
41.3 (13.6–NE) 1.23 (0.41–3.67; 0.709)
ne; Ex19del, deletion in exon 19; HR, hazard ratio; G, geﬁtinib
21; NE, not estimable; PC/G, pemetrexed plus cisplatin followed
Figure 2. Kaplan-Meier analysis of OS in the ITT population by EGFR mutation status and by postdiscontinuation therapy. OS
in the PC/G and G groups in the ITT population (A), EGFR wild-type subgroup (B), EGFR-mutated subgroup (C), Ex19del
subgroup (D), and L858R subgroup (E). OS in the G group for patients receiving a pemetrexed platinum doublet as second-line
PDT and those receiving a nonpemetrexed platinum doublet (F). EGFR, epidermal growth factor receptor gene; Ex19del,
deletion in exon 19; G, geﬁtinib monotherapy; ITT, intention-to-treat; L858R, point mutation in exon 21; non-Pem, non-
pemetrexed platinum doublet; OS, overall survival; PC/G, pemetrexed plus cisplatin followed by maintenance geﬁtinib; PDT,
postdiscontinuation therapy; Pem, pemetrexed platinum doublet.
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wild-type tumors and longer with G in patients with
EGFR-mutated tumors, although these differences in
OS were not statistically signiﬁcant. For patients who
progressed while receiving ﬁrst-line G, OS appeared to
be longer in patients who received a pemetrexedplatinum doublet as second-line treatment than
in those who received a nonpemetrexed platinum
doublet. As observed at the time of the primary
analysis, both treatment regimens were associated
with a manageable safety proﬁle. The results from this
study provide further support for EGFR mutation
Table 3. Postdiscontinuation Therapy
PDT
PC/G
(n ¼ 118)
n (%)
G
(n ¼ 118)
n (%) p Value
Second-line PDTwith
systemic treatment
71 (60.2) 85 (72.0) 0.074
Chemotherapy 41 (34.7) 73 (61.9) <0.001
Platinum doublet 15 (12.7) 56 (47.5) <0.001
Pemetrexed platinum
doublet
4 (3.4) 33 (28.0) NA
Nonpemetrexed
platinum doublet
11 (9.3) 23 (19.5) NA
Single agent 24 (20.3) 17 (14.4) 0.303
Nonplatinum doublet 2 (1.7) 0 (0) 0.498
EGFR TKI 27 (22.9) 9 (7.6) 0.002
Afatinib 0 (0) 1 (0.8) 1.000
Erlotinib 12 (10.2) 1 (0.8) 0.003
Geﬁtinib 14 (11.9) 7 (5.9) 0.169
Geﬁtinib þ
investigational
agent
1 (0.8) 0 (0) 1.000
EGFR, epidermal growth factor receptor; G, geﬁtinib mono-
therapy; NA, not applicable; PC/G, pemetrexed plus cisplatin
followed by maintenance geﬁtinib; PDT, postdiscontinuation ther-
apy; TKI, tyrosine kinase inhibitor.
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tients with advanced NSCLC, rather than relying
solely on clinical characteristics to select the most
appropriate treatment.
OS in the Overall Study Population
As observed for the primary analysis of PFS,11 there
was no signiﬁcant difference in OS between PC/G and
G in the overall population in this study. These OS
results are consistent with those of two randomized
phase 3 studies of chemotherapy versus geﬁtinib in
chemonaive patients who were clinically selected to
respond to geﬁtinib (i.e., East Asian never-smokers or
light ex-smokers with adenocarcinoma).16,17 Specif-
ically, the IPASS found no signiﬁcant difference in OS
between patients receiving up to six cycles of
carboplatin-paclitaxel (n ¼ 608, median OS 17.4
months) and patients receiving geﬁtinib (n ¼ 609,
median OS 18.8 months).16 Likewise, the First-SIGNAL
study found no signiﬁcant difference in OS between
patients receiving up to nine cycles of gemcitabine-
cisplatin (n ¼ 150, median OS 22.9 months) and pa-
tients receiving geﬁtinib (n ¼ 159; median OS 22.3
months).17 The authors of these two studies stated that
the high proportions of patients in the chemotherapy
and geﬁtinib groups receiving the alternative treat-
ment as PDT may have confounded the true effect of
the ﬁrst-line treatment on OS.16,17 In the current study,
it should be noted that in addition to second-line PDTbeing common in the two treatment groups, patients
who had not progressed after six cycles of chemo-
therapy received maintenance geﬁtinib, which may
also have contributed to the lack of difference in OS
between the two treatment groups in the overall study
population.
OS in Patients with EGFR Wild-Type Tumors
In the current study, median OS was longer with
PC/G than with G in the subgroup of patients with EGFR
wild-type tumors. This ﬁnding is in line with the PFS
results of the primary analysis,11 the IPASS,12 and the
First-SIGNAL study,17 all of which demonstrated longer
PFS (signiﬁcantly longer in the primary analysis and
the IPASS) with chemotherapy (plus maintenance
geﬁtinib in the current study) than with geﬁtinib in
patients with EGFR wild-type tumors. Unlike in the
current study, however, OS was similar between
treatment groups in patients with EGFR wild-type tu-
mors in the IPASS and First-SIGNAL study.16,17 In the
IPASS, median OS was 12.7 months in patients with
EGFR wild-type tumors who received carboplatin-
paclitaxel (n ¼ 85) and 11.2 months in patients
receiving geﬁtinib (n ¼ 91).16 In the First-SIGNAL
study, median OS was 21.9 months in patients with
EGFR wild-type tumors who received gemcitabine-
cisplatin (n ¼ 27) and 18.4 months in patients
receiving geﬁtinib (n ¼ 27).17 The lack of signiﬁcant
difference in OS in the EGFR wild-type subgroups in
these two studies was attributed to the use of PDT. For
instance, 75.8% of patients with EGFR wild-type tumors
who received geﬁtinib in the IPASS subsequently
received chemotherapy as PDT.16
OS in Patients with EGFR-Mutated Tumors
In the current study, median OS was longer with G
than with PC/G in the subgroup of patients with EGFR-
mutated tumors. In contrast, OS was similar between
chemotherapy and geﬁtinib in the subgroups of pa-
tients with EGFR-mutated tumors in the IPASS and
First-SIGNAL study.16,17 Speciﬁcally, in the IPASS, me-
dian OS was 21.9 months in patients with EGFR-
mutated tumors who received carboplatin-paclitaxel
(n ¼ 129) and 21.6 months in patients receiving geﬁ-
tinib (n ¼ 132).16 In the First-SIGNAL study, median OS
was 25.6 months in patients with EGFR-mutated tu-
mors who received gemcitabine-cisplatin (n ¼ 16) and
27.2 months in patients receiving geﬁtinib (n ¼ 26).17
In addition, two randomized phase 3 studies of che-
monaive patients with advanced NSCLC (WJTOG3405
[N ¼ 172] and NEJ002 [N ¼ 228]), which enrolled only
patients with EGFR-mutated tumors, found no signiﬁ-
cant difference in OS between chemotherapy and geﬁ-
tinib.18–21 Again, the frequent use of PDT in these
March 2016 Pemetrexed plus Cisplatin Followed by Geﬁtinib 377studies likely contributed to the lack of signiﬁcant
difference in OS between chemotherapy and geﬁtinib in
patients with EGFR-mutated tumors. It is possible that
the EGFR testing method, the proportion of patients
receiving PDT, and the prevalence of pemetrexed
treatment may have inﬂuenced the variation in out-
comes between the current study and the other studies
described here.
The current study assessed sequential administration
of chemotherapy and an EGFR TKI; however, another
possible treatment strategy for patients with NSCLC and
EGFR-mutated tumors is concurrent administration of
chemotherapy and EGFR TKI. Cheng et al.22 recently
assessed concurrent administration of pemetrexed and
geﬁtinib in 191 patients with nonsquamous NSCLC with
EGFR-mutated tumors, reporting a signiﬁcant improve-
ment in PFS with pemetrexed plus geﬁtinib versus with
G (median PFS was 15.8 months for pemetrexed plus
geﬁtinib versus 10.9 months for G; HR ¼ 0.68, 95% CI:
0.48–0.96, one-sided p ¼ 0.014; two-sided p ¼ 0.029).
Further investigation of different combinations and
timing of chemotherapy and EGFR TKIs may expand the
treatment strategies available for patients with NSCLC
and EGFR-mutated tumors.
OS in Patients with Exon 19 Deletions or the
L858R Point Mutation
Analysis of OS by the two most common EGFR
mutations revealed longer OS with G than with PC/G
in patients with exon 19 deletions and in patients
with the L858R point mutation; however, the differ-
ence in OS between the two treatment regimens
appeared to be more marked for the exon 19 dele-
tion than for the L858R point mutation. A similar
pattern was observed for PFS in the IPASS, in which
PFS was signiﬁcantly longer for geﬁtinib than for
carboplatin-paclitaxel in both the exon 19 deletion
and L858R subgroups, with a slightly greater
advantage in the exon 19 deletion subgroup.16 In
addition, preplanned analyses of two randomized
phase 3 studies of the EGFR TKI afatinib versus
chemotherapy (LUX-Lung 3 [N ¼ 345] and LUX-Lung
6 [N ¼ 364]) showed signiﬁcantly longer OS with
afatinib than with chemotherapy in patients with
exon 19 deletions, but not in patients with the L858R
point mutation.23 These results suggest that patients
with exon 19 deletions may be more responsive to
EGFR TKI treatment compared with chemotherapy
than are patients with the L858R point mutation.
Direct comparisons of the effect of exon 19 deletions
and the L858R point mutation on treatment out-
comes in patients with advanced NSCLC have yielded
different results. Reports from retrospective ana-
lyses, phase 2 studies, a database of ﬁve studies fromthe United States and Europe, and a meta-analysis
have noted longer PFS and/or OS after treatment
with an EGFR TKI in patients with exon 19 dele-
tions than in patients with the L858R point muta-
tion.10,24–27 However, other studies, including the
phase 3 studies IPASS, WJTOG3405, and NEJ002,
found no signiﬁcant difference in PFS after geﬁtinib
treatment in patients with exon 19 deletions
compared with patients having the L858R point
mutation.16,18,21 The individual effects of exon 19
deletions and the L858R point mutation on treatment
outcomes with EGFR TKIs remain to be fully eluci-
dated and may depend on the individual EGFR TKI.23
Nevertheless, the current study provides further ev-
idence for improved outcomes in patients with exon
19 deletions and highlights the need for prospective
research in this ﬁeld.
Second-Line PDT
As expected, signiﬁcantly more patients in the PC/
G group received an EGFR TKI as second-line PDT and
signiﬁcantly more patients in the G group received
chemotherapy. Analysis of OS by PDT in the G group
revealed longer OS in patients who received second-
line treatment with a pemetrexed platinum doublet
than in those who received a nonpemetrexed plat-
inum doublet. As patients were not randomly
assigned to the type of second-line chemotherapy,
deﬁnitive conclusions cannot be drawn from this
small, retrospective post hoc analysis and the p value
should be interpreted with caution. Nevertheless,
these results are in keeping with pemetrexed being a
recommended treatment for chemotherapy-naive and
pretreated patients with nonsquamous NSCLC,3–5 and
they suggest that pemetrexed-based chemotherapy
may be superior to nonpemetrexed-based chemo-
therapy after progression during administration of an
EGFR TKI. In addition, recent results from a ran-
domized phase 3 study (Iressa Mutation Positive
Multicentre Treatment Beyond Progression Study)
have shown that the pemetrexed-cisplatin doublet is
active in patients with advanced NSCLC with EGFR
mutations who have progressed while receiving ﬁrst-
line geﬁtinib treatment and that continuation of geﬁ-
tinib in combination with pemetrexed-cisplatin does
not improve outcomes in patients with acquired
resistance to geﬁtinib.28
Safety
The updated safety results reported from this
analysis are similar to those reported at the time of
the primary analysis11 and are consistent with the
known safety proﬁles of pemetrexed, cisplatin, and
geﬁtinib.29–31
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The requirement that patients have unknown tumor
EGFR mutation status at study entry was intended to
reﬂect clinical practice, in which EGFR mutation status is
not always known when treatment decisions are made.
EGFR mutation testing after study entry allowed
assessment of OS by EGFR mutation status. However, a
limitation of the study was that tumor EGFR mutation
status could be determined for only a small proportion
of patients, which should be kept in mind when inter-
preting the OS results for these subgroups, as should the
retrospective nature of these analyses. The challenges of
sample acquisition and EGFR mutation testing further
highlight the importance of selecting the appropriate
treatment strategy in patients with unknown tumor
EGFR mutation status. On the basis of the HR for PFS
favoring PC/G in the overall study population11 and the
wild-type EGFR subgroup not beneﬁtting from treatment
with G,11 we suggest that chemotherapy is the preferred
treatment option in patients with unknown tumor EGFR
mutation status, including those patients with clinical
characteristics associated with response to an EGFR TKI.
However, the patient’s EGFR mutation status is of the
utmost importance in making this treatment decision
and should be determined whenever possible. In
considering the limitations of this study, it should also be
noted that the study was not powered to evaluate the
difference in OS between the two treatment regimens.Conclusions
In this population of patients with advanced NSCLC
who were clinically selected to respond to geﬁtinib, OS
was not prolonged by PC/G compared with by G. This fact
is consistent with the primary analysis ﬁnding that there
was no signiﬁcant difference in PFS between the two
treatment regimens in this patient population.11 Notably,
OS appeared to be longer with PC/G in patients with EGFR
wild-type tumors and with G in patients with EGFR-
mutated tumors, especially in those patients with exon 19
deletions. In patients who progressed while receiving
ﬁrst-line geﬁtinib treatment, OS appeared to be longer in
patients who received a pemetrexed platinum doublet as
second-line treatment than in those who received a non-
pemetrexedplatinumdoublet. In conjunctionwith the PFS
results from the primary analysis, the ﬁnal OS data from
this randomized phase 3 study further demonstrate the
importance of determining EGFRmutation status to guide
selection of the most appropriate ﬁrst-line treatment for
patients with advanced NSCLC.
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